# Will the FDA approve a seasonal influenza vaccine for the 2025-2026 flu season before October 1, 2025? (QID: 38824)

- Type: binary

- URL: https://www.metaculus.com/questions/38824/

- Classifier: health | strategic=False (score=0.00)

## Research (summary)

CALIBRATION GUIDANCE (auto-generated weekly):
BINARY CALIBRATION
- No resolved binary questions (with pre-resolution forecasts) yet.
- Advice: keep using base rates + small evidence-weighted updates; avoid big swings.

MULTIPLE-CHOICE CALIBRATION (Top-1)
- No resolved MCQ questions (with pre-resolution forecasts) yet.

NUMERIC CALIBRATION (PIT-lite + CRPS)
- No resolved numeric questions (with pre-resolution forecasts) yet.
- When numeric results exist, we’ll check p10/p50/p90 coverage and CRPS.

General takeaway: apply **small** nudges only where gaps are consistent with decent sample sizes (≥10).
— end calibration —

### Reference class & base rates
- **Annual FDA Influenza Vaccine Approvals**: Historically, the FDA has approved seasonal influenza vaccines annually since 1973, with a base rate of 100% approval before the flu season.
- **FDA Advisory Committee Meetings**: Typically held annually for strain selection, with a high likelihood of proceeding unless significant disruptions occur.

### Recent developments (timeline bullets)
- [2025-02-26] ↓ — FDA canceled March VRBPAC meeting, disrupting the usual vaccine approval timeline.
- [2025-01-XX] ↓ — U.S. began WHO withdrawal, potentially affecting international collaboration on strain selection.

### Mechanisms & drivers (causal levers)
- **Regulatory Process**: Large — FDA's established process for vaccine approval.
- **Political Influence**: Moderate — Executive orders affecting international health collaborations.
- **Public Health Policy**: Moderate — Changes in communication with WHO and CDC.
- **Manufacturing Timelines**: Small — Time required for vaccine production post-approval.
- **Public Pressure**: Small — Demand for vaccines can influence expedited approvals.

### Differences vs. the base rate (what’s unusual now)
- **Canceled VRBPAC Meeting**: Unprecedented disruption in the approval process timeline.
- **Political Climate**: Increased political interference in health policy decisions.
- **International Collaboration**: Reduced due to WHO withdrawal, affecting strain selection.
- **Communication Gaps**: Delays in CDC and FDA coordination due to postponed meetings.

### Bayesian update sketch (for the statistician)
- **Prior**: High likelihood of approval based on historical consistency (equivalent n = 50+ years).
- **Evidence mapping**:
  - ↓ Large — Canceled VRBPAC meeting.
  - ↓ Moderate — WHO withdrawal and communication halts.
  - ↓ Small — Delayed CDC meeting.
- **Net effect**: Posterior should move down moderately due to significant disruptions in the approval process.

### Indicators to watch (leading signals; next weeks/months)
- **UP indicators**:
  - Rescheduling of VRBPAC meeting.
  - New executive orders supporting vaccine approval.
  - Increased public health communication efforts.
- **DOWN indicators**:
  - Continued delays in CDC and FDA meetings.
  - Further political interference in health policy.
  - Lack of updates on strain selection.

### Caveats & pitfalls
- **Uncertainty in Political Decisions**: Rapid policy changes can alter the landscape.
- **Data Gaps**: Limited information on internal FDA deliberations.
- **Deception Risks**: Potential misinformation regarding approval status.
- **Regime Changes**: Shifts in political leadership affecting health policy.
- **Definitional Gotchas**: Ambiguity in what constitutes "approval" before the deadline.

Final Research Summary: The likelihood of FDA approval for the 2025-2026 flu vaccine before October 1, 2025, is lower than usual due to significant disruptions in the approval process, including the canceled VRBPAC meeting and political influences affecting international collaboration.

### Sources (autofetched)
- Game Recap: Eagles 20, Chiefs 17 | September 14, 2025 | NFL Regular Season Week 2 (philadelphiaeagles.com) — https://www.philadelphiaeagles.com/news/eagles-vs-chiefs-game-recap-september-14-2025-nfl-week-2
- Buckeyes Head to Inverness Club for Second Tournament of the Season (ohiostatebuckeyes.com) — https://ohiostatebuckeyes.com/news/2025/9/14/womens-golf-buckeyes-head-to-inverness-club-for-second-tournament-of-the-season
- Bears Continue Impressive Start To Season (calbears.com) — https://calbears.com/news/2025/9/14/mens-water-polo-bears-continues-impressive-start-to-season.aspx
- SMU Wraps Season Opener At Waco Fall Kickoff Classic (smumustangs.com) — https://smumustangs.com/news/2025/9/14/mens-tennis-smu-wraps-season-opener-at-waco-fall-kickoff-classic.aspx
- Men’s Tennis Starts Fall Season at River Forest Collegiate Invitational (niuhuskies.com) — https://niuhuskies.com/news/2025/9/14/mens-tennis-mens-tennis-starts-fall-season-at-river-forest-collegiate-invitational.aspx
- Buffs Trample Pioneers in Seventh Sweep of Season (cubuffs.com) — https://cubuffs.com/news/2025/9/14/volleyball-buffs-trample-pioneers-in-seventh-sweep-of-season
- Women's Golf Opens Season With Second Place at Batchelder Match Play (athletics.bowdoin.edu) — https://athletics.bowdoin.edu/news/2025/9/14/womens-golf-opens-season-with-second-place-at-batchelder-match-play.aspx
- Rams fall 2-1 at Denver for first loss of season (csurams.com) — https://csurams.com/news/2025/9/14/womens-soccer-rams-fall-2-1-at-denver-for-first-loss-of-season

## Per-model

- **OpenRouter-Default** ok=True time=20512ms cost=$10.9750 parsed=0.85

  - Raw output (excerpt):

    1. **Base Rate (Prior) Selection**
       - The historical base rate for FDA approval of seasonal influenza vaccines is 100%, given the uninterrupted annual approval process since 1973. This high base rate is due to the established regulatory process and the public health importance of flu vaccines.
       - Initial prior probability: 100%.
    
    2. **Comparison to Base Case**
       - Similarities: The FDA has a long-standing process for approving flu vaccines, which typically involves annual meetings and strain selection.
       - Differences: The cancellation of the VRBPAC meeting and political changes, such as the U.S. withdrawal from the WHO, introduce significant disruptions not present in previous years. These differences could delay or complicate the approval process.
    
    3. **Evidence Evaluation (Likelihoods)**
       - Canceled VRBPAC Meeting: This is a significant disruption. The likelihood of this happening if the vaccine is approved (P(E | H)) is low compared to if it is not approved (P(E | ~H)), suggesting a likelihood ratio < 1, decreasing the probability.
       - WHO Withdrawal: This reduces international collaboration, which is important for strain selection. Again, P(E | H) is lower than P(E | ~H), decreasing the probability.
       - Delayed CDC Meeting: This further complicates coordination, with a similar likelihood ratio < 1, decreasing the probability.
    
    4. **Bayesian Updating (Posterior Probability)**
       - Prior odds = 100% / (1 - 100%) = ∞ (since the base rate is 100%).
       - Likelihood ratio for the combined evidence is significantly less than 1 due to the disruptions.
       - Posterior odds = Prior odds × Likelihood ratio = ∞ × <1 = still high but reduced.
       - Posterior probability is still high but less than 100% due to the significant disruptions.
    
    5. **Red Team Thinking**
       - Overconfidence risk: The historical base rate is very high, but current disruptions are unprecedented.
       - Alternative scenario: If political and logistical issues are resolved quickly, the probability could be higher.
       - Adjustments: Consider the possibility of rapid policy changes or rescheduling of meetings, which could increase the probability.
    
    6. **Final Forecast**
       - Given the historical base rate and the current disruptions, the probability of FDA approval before October 1, 2025, is reduced but remains relatively high due to the importance of flu vaccines and potential for resolving disruptions.
       - Final: 85%

## Ensembles (with research)

- main=0.7903 | no_gtmc1=0.7903 | uniform=0.7903 | simple=0.8500

## Ablation (no research)

- main=0.6668 | uniform=0.6668 | simple=0.7000
